

Convex Europe S.A.

Product Oversight and Governance

PRODUCT PASSPORT

CVX-CAS-008-0225

Excess of Loss Liability Policy (ROI)



1. Summary

As a manufacturer of insurance products, we are required to provide you with information to enable the compliant sale of our products. The information contained in this document should support you in:

- Understanding the Convex product being distributed
- Identifying the appropriate target market
- Observing requirements of the Insurance Distribution Directive
- Safeguarding the best interests of the target market

We further outline the requirements of product oversight & governance (POG) rules and the respective roles and responsibilities of manufacturers and distributors.

2. Product Oversight and Governance

Product Oversight and Governance ("POG") refers to the systems and controls firms have in place to design, approve, market, and manage products throughout the products' lifecycle to ensure they meet legal/regulatory requirements and deliver fair value to customers.

POG is principally governed by the Insurance Distribution Directive (EU) 2017/2358. The Directive applies to all firms that manufacture and distribute insurance products in the UK/EU, however, care should be taken to identify any additional local rules that may apply on a state level. The information in this guide is limited to the requirements of the IDD and UK FCA product governance rules (PROD 4).

3. POG Roles and Responsibilities

Maintaining effective oversight and governance arrangements is the responsibility of both 'Manufacturers' and 'Distributors'. A Manufacturer is "a firm which creates, develops, designs and/or underwrites a contract of insurance", whereas a Distributor is anyone engaged in advising on or proposing contracts of insurance.

As a carrier, Convex is deemed a manufacturer, however, in some instances, there will be comanufacture between Convex and another insurer or distributor. Co-manufacturing occurs when two or more parties have a "decision-making role in determining the essential features and main elements of a product, including coverage, price, costs, risks, target market and compensation/guarantee rights".



3.1 Manufacturer's Responsibilities

It is the responsibility of (co)manufacturers to furnish distributors with appropriate information to guide the distribution of products. In addition, manufacturers must maintain a product approval process to:

- Identify suitable/non suitable target markets for products
- Conduct product testing
- Select appropriate distribution channels
- Periodically monitor and review products
- Develop insurance product documents (IPIDs)

The allocation of POG responsibilities between co-manufacturers will be reflected in the IDD endorsement of the Binding Authority Agreement or Slip.

Manufacturers must also ensure that staff engaged in the development and distribution of products complete a minimum of 15 hours relevant CPD training per annum.

3.2 Distributors Responsibilities

It is the responsibility of all distributors to maintain up to date knowledge of the product being sold, its intended target market, the needs of that market, and the distribution strategy. As per IDD requirements, regulated distributors must complete a minimum of 15 hours CPD training covering:

- The terms and conditions of product(s) being sold
- Relevant knowledge of claims handling
- Relevant knowledge of complaints handling
- Relevant knowledge of applicable laws/regulations governing distribution of the product
- Assessment of customer needs
- Business ethics standards
- Minimum necessary financial competency

Distributors must obtain from the manufacturer all the information required to distribute products in accordance with IDD requirements. Should further information be needed to enable the compliant distribution of a Convex product, please notify your Convex contact.

Distributors must make this product passport available to all approved sub agents/ intermediaries in the distribution chain.

Distributors must also regularly report to Convex the sales, claims, and complaints information it accumulates in relation to a Convex product. In addition, an annual questionnaire will be sent to distribution partners to monitor the ongoing fair value of products.

Lastly, distributors must be alert to and promptly notify Convex of any product related circumstances that may adversely affect the interests of customers.



Product Details		
Product Name	Excess of Loss Liability Policy (ROI)	
Product Reference	CVX-CAS-008-0225	
Product Manufacturer	Convex Europe S.A.	
Line of Business	Casualty	
Binding Authority Reference	N/A	
Effective Date	22/05/2025	
Date of Last Review	22/05/2025	

Product Description

This excess of loss ("XOL") product provides additional limits to commercial customers operating business located in the Republic of Ireland by offering cover that sits above their primary liability insurance policy ("Primary Policy"). As a market standard follow form wording, the terms and conditions of the XOL predominantly follow those within the Primary Policy.

The XOL product has a number of separate sections to cover a broad range of risks to business with each of these sections being optional and priced individually.

Product Features	
Covers	Main covers:
	1. Employers' Liability
	2. Public & Pollution Liability
	3. Product Liability
Key Exclusions	The policy does not insure, apply to or include any cover for any loss, damage, Claim, cost, expense or other sum directly or indirectly arising out of or relating to:
	1. Cyber
	2. Communicable disease
	3. War
	4. Terrorism
	5. Sanctions



	6. PFAS
	Exclusions in the Primary Policy will also apply, although in case of conflict the exclusions in the XOL wording will take precedence.
	Some of the above exclusions do not apply to some of the covers (for instance, Employers' Liability), as further specified in the Primary Policy and XOL product.
Main Restrictions	As limited in the Schedule
Optional Covers	None
Cross-selling/ Ancillary/Packaged Product	N/A
Claims Settlement Bases	Indemnity against legally liable Damages and Defence costs
Frequently Challenged Policy Terms	None
Policy Length	Variable but usually annual ± odd time.
Policy Structure	This product is to be sold to individual insureds.

Target Market Analysis		
Product Complexity	The technicality of this product and the intended distribution strategy is suitable for the intended target market. The wording and operation of the product has been designed to meet the needs and sophistication of commercial clients.	
Target Market	This product is intended for SME and Large ROI commercial entities for a wide range of industry sectors.	
Risks associated with Target Market	There are no material risks/vulnerabilities associated with the intended target market.	
Product Unsuitability	The product is suitable for both commercial entities and consumers in the Republic of Ireland.	

Fair Value Assessment	
Fair Value Statement	Fair value means the relationship between the overall price paid by the end customer and the quality of the product(s) and/or service(s) received.
	Our fair value assessment considers value measures such as:



	Complaints
	 Broker feedback
	 Commission and fees
	Staff remuneration
	Pricing models
	Claims stats
	Cancellation rates
	 Premium finance arrangements
	Based on our assessment of the above metrics we conclude that the product provides fair value to the target market.
Distribution Chain Value	The distribution strategy represents value for money, commissions and fees reflect services rendered and there are no superfluous intermediaries in the chain. The overall method of distribution is cost effective (refer to commissions/fees and price setting above).
Remuneration / Sales Incentives	Volume dependent remuneration should be avoided and must not conflict with the best interests of the customer.
Premium Finance Arrangements	Premium finance arrangements are subject to approval by Convex Europe S.A

Distribution Strategy	
Approved Distribution Channels	The distribution channel is via a select number of EU regulated intermediaries only.
Special Distribution/Servicing Arrangements	N/A
Delegated Authority	This product is suitable for distribution via delegated authority subject to approval by Convex and the terms of a Binding Authority Agreement.
Sales Type	This product is to be sold on an advised basis only.
Online Sales	This product may be distributed via online sales. All marketing materials must be formally reviewed for regulatory compliance by the distributor prior to publication.

Conflicts & Risks



No conflicts or risks identified. Where a conflict is identified by the distributor it must be mitigated appropriately, recorded, and communicated to Convex.



Convex Re Limited Point House, 6th Floor, 6 Front Street, Hamilton HM 11, Bermuda

Convex Insurance UK Limited

52 Lime Street, London, EC3M 7AF

Convex Europe S.A.

37 Boulevard Joseph II, 2ème étage, L-1840 Luxembourg, Grand-Duchy of Luxembourg

Convex Europe S.A. UK Branch

52 Lime Street, London, EC3M 7AF

Convex Guernsey Limited

Bucktrout House, Glategny Esplanade, St Peter Port, Guernsey, GY1 1WR

Convex North America Insurance Services LLC

47 Hulfish Street, Suite 310, Princeton, NJ 08542

convexin.com

Convex Group is the trading name of Convex Group Limited, a company incorporated in Bermuda, and the ultimate parent company of the Convex Group of companies, which includes the following regulated entities: Convex Re Limited, a company incorporated in Bermuda which is licensed and supervised by the Bermuda Monetary Authority; Convex Insurance UK Limited, a company incorporated in England & Wales which is authorised by the Prudential Regulation Authority (PRA) and regulated by the Financial Conduct Authority (FCA) and the PRA; Convex North America Insurance Services LLC, a company incorporated in Delaware which is a US managing general underwriter and licensed excess and surplus lines insurance broker; Convex Europe S.A. a company incorporated in Luxembourg which is supervised by the PRA. Details about the extent of its regulation and Convex Europe S.A. UK Branch which is authorised and regulated by the CAA and authorised by the PRA and subject to regulation by the FCA and limited regulation by the PRA. Details about the extent of its regulation by the PRA are available from us on request.